RxDoctor Payments Data

Jacquelynn Hoffman, APRN

Psychiatric/Mental Health · Georgetown, KYNPI 1306490248

Payments from drug & device makers

$2,515in general payments, 2019–2025

Across 52 payments — averaging $48.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$939
  • Neurocrine Biosciences, Inc.$469
  • Alkermes, Inc.$216
  • Avanir Pharmaceuticals, Inc.$208
  • Teva Pharmaceuticals USA, Inc.$181
  • E.r. Squibb & Sons, L.L.C.$167
  • plus $334 from 5 others

What the payments were for

  • Food & beverage$2,507100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,515 in reported general payments places this provider in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$115,210
Medicare patients
472
Services billed
1,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$153,746
NuplazidPimavanserin Tartrate12$48,969
RexultiBrexpiprazole34$24,138
Divalproex Sodium228$15,908
VraylarCariprazine Hcl18$12,380
Sertraline Hcl609$8,738
Paliperidone ErPaliperidone43$8,624
Mirtazapine181$4,783
Fluoxetine Hcl249$4,276
Clozapine23$3,864
Risperidone138$3,781
Memantine Hcl102$3,451
Trazodone Hcl218$3,434
Olanzapine72$3,373
Doxepin Hcl35$3,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$469$153,74618 claims
Acadia Pharmaceuticals IncNuplazid$939$48,96912 claims
Otsuka America Pharmaceutical, Inc.Rexulti$56$24,13834 claims
AbbVieVraylar$75$12,38018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →